OSCR
Oscar Health, Inc.
OSCR has the edge over UHS overall, supported by stronger fundamentals and stronger modeled upside.
UHS
Universal Health Services, Inc.
UHS has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
UHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
UHS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over UHS in the historical PE scenario, which offers more potential upside but is not a forecast.
UHS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8.1x | $194 | — |
| Forward | 8.6x | $194 | — |
| Cheap | 9.7x | $231 | +19% |
| Fair | 12x | $296 | +53% |
| Expensive | 15x | $367 | +89% |
Historical ranges are pointers, not guarantees.
UHS's PE is in its cheap range at 8.1x. On analysts' estimates for next year's earnings, today's price would be 8.6x.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over UHS on the outlook, with more favorable valuation and earnings expectations.
UHS Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect UHS's revenue to grow, but its profitability to weaken.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
UHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.52 | -5.6% |
| Q3 2026 | $23.86 | +13% |
| Q2 2026 | $24.50 | +29% |
| Q1 2026 | $23.95 | +35% |
| Q4 2025 | $23.10 | +37% |
| Q3 2025 | $21.03 | +40% |
| Q2 2025 | $18.97 | +39% |
| Q1 2025 | $17.80 | +51% |
| Q4 2024 | $16.82 | +64% |
UHS has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over UHS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
UHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.7B | +5.3% |
| Q2 2026 | $4.6B | +8.3% |
| Q1 2026 | $4.5B | +9.6% |
| Q4 2025 | $4.5B | +9.1% |
| Q3 2025 | $4.5B | +13% |
| Q2 2025 | $4.3B | +9.6% |
| Q1 2025 | $4.1B | +6.7% |
| Q4 2024 | $4.1B | +11% |
UHS's revenue has grown year over year every quarter since late 2020: $4.7B last quarter, up 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | -2 points |
| Q2 2026 | 11% | -0.5 points |
| Q1 2026 | 11% | +0.1 points |
| Q4 2025 | 12% | 0 points |
| Q3 2025 | 12% | +1.9 points |
| Q2 2025 | 12% | +0.5 points |
| Q1 2025 | 11% | +1 points |
| Q4 2024 | 11% | +2.6 points |
UHS has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over UHS on cash flow, with more consistent year-over-year improvement.
UHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $421.6M | +178% |
| Q2 2026 | $215.7M | -24% |
| Q1 2026 | $184.5M | +52% |
| Q4 2025 | $293.5M | -29% |
| Q3 2025 | $151.8M | +78% |
| Q2 2025 | $283M | -35% |
| Q1 2025 | $121M | -36% |
| Q4 2024 | $412.5M | +68% |
UHS still generates free cash flow, though less than at its 2020 peak: $1.1B over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
UHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -765K shares |
| 1 year | -7.1% | -4.5M shares |
| 3 years | -15% | -10.5M shares |
| 5 years | -29% | -24.5M shares |
| Available history | -34% | -29.9M shares |
UHS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $245.3M |
| Q2 2026 | $320.8M |
| Q1 2026 | $163.8M |
| Q4 2025 | $352M |
| Q3 2025 | $237.4M |
| Q2 2025 | $155.2M |
| Q1 2025 | $223.4M |
| Q4 2024 | $250.2M |
UHS spent $1.1B buying back its own shares over the past year, up 25% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over UHS on leverage, with a lower net debt burden relative to earnings.
UHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.8x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.9x | Healthy |
UHS's net debt is about 2.1 years of its operating earnings (EBITDA), up from 1.8 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
UHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.4 | Neutral |
| Stochastic | 71.1 | Neutral |
UHS's weekly RSI is 60 (neutral) and its Stochastic is 71 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
UHS PE vs Healthcare Sector
| Metric | UHS | Sector median | Relative |
|---|---|---|---|
| PE | 8.1x | 26x | 69% below |
| PE % | 9 | 29 | 20 pts below |
UHS has the edge over OSCR on valuation relative to its sector.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
UHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $183.7 | 5.5% above |
| 20 week MA | $173.6 | 12% above |
| 50 week MA | $183.2 | 5.8% above |
| 100 week MA | $185.2 | 4.7% above |
| 200 week MA | $174.6 | 11% above |
UHS is in an uptrend: it's above all five of its weekly moving averages, and 11% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over UHS on returns for 2026, with the stronger performance.
UHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $143.4 | $136.9 | -4.5% |
| 2021 | $136.9 | $128.1 | -6.4% |
| 2022 | $128.1 | $140.8 | +9.9% |
| 2023 | $140.8 | $152.4 | +8.3% |
| 2024 | $152.4 | $180.5 | +18% |
| 2025 | $180.5 | $227.6 | +26% |
| 2026 YTD | $227.6 | $193.8 | -15% |
UHS has finished higher in four of the last six years. It's down 15% so far in 2026.